Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2018

01-07-2018 | Epidemiology

Dose-dependent effect of mammographic breast density on the risk of contralateral breast cancer

Authors: Marzana Chowdhury, David Euhus, Maureen O’Donnell, Tracy Onega, Pankaj K. Choudhary, Swati Biswas

Published in: Breast Cancer Research and Treatment | Issue 1/2018

Login to get access

Abstract

Purpose

Increased mammographic breast density is a significant risk factor for breast cancer. It is not clear if it is also a risk factor for the development of contralateral breast cancer.

Methods

The data were obtained from Breast Cancer Surveillance Consortium and included women diagnosed with invasive breast cancer or ductal carcinoma in situ between ages 18 and 88 and years 1995 and 2009. Each case of contralateral breast cancer was matched with three controls based on year of first breast cancer diagnosis, race, and length of follow-up. A total of 847 cases and 2541 controls were included. The risk factors included in the study were mammographic breast density, age of first breast cancer diagnosis, family history of breast cancer, anti-estrogen treatment, hormone replacement therapy, menopausal status, and estrogen receptor status, all from the time of first breast cancer diagnosis. Both univariate analysis and multivariate conditional logistic regression analysis were performed.

Results

In the final multivariate model, breast density, family history of breast cancer, and anti-estrogen treatment remained significant with p values less than 0.01. Increasing breast density had a dose-dependent effect on the risk of contralateral breast cancer. Relative to ‘almost entirely fat’ category of breast density, the adjusted odds ratios (and p values) in the multivariate analysis for ‘scattered density,’ ‘heterogeneously dense,’ and ‘extremely dense’ categories were 1.65 (0.036), 2.10 (0.002), and 2.32 (0.001), respectively.

Conclusion

Breast density is an independent and significant risk factor for development of contralateral breast cancer. This risk factor should contribute to clinical decision making.
Literature
1.
go back to reference Tuttle TM, Habermann EB, Grund EH et al (2007) Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol 25:5203–5209CrossRefPubMed Tuttle TM, Habermann EB, Grund EH et al (2007) Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol 25:5203–5209CrossRefPubMed
2.
go back to reference Tuttle TM, Jarosek S, Habermann EB et al (2009) Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol 27:1362–1367CrossRefPubMed Tuttle TM, Jarosek S, Habermann EB et al (2009) Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol 27:1362–1367CrossRefPubMed
3.
go back to reference King TA, Sakr R, Patil S et al (2011) Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J Clin Oncol 29:2158–2164CrossRefPubMed King TA, Sakr R, Patil S et al (2011) Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J Clin Oncol 29:2158–2164CrossRefPubMed
4.
go back to reference Yao K, Stewart AK, Winchester DJ, Winchester DP (2010) Trends in contralateral prophylactic mastectomy for unilateral cancer: a report from the national cancer data base, 1998–2007. Ann Surg Oncol 17:2554–2562CrossRefPubMed Yao K, Stewart AK, Winchester DJ, Winchester DP (2010) Trends in contralateral prophylactic mastectomy for unilateral cancer: a report from the national cancer data base, 1998–2007. Ann Surg Oncol 17:2554–2562CrossRefPubMed
5.
go back to reference Katipamula R, Degnim AC, Hoskin T et al (2009) Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging. J Clin Oncol 27:4082–4088CrossRefPubMedPubMedCentral Katipamula R, Degnim AC, Hoskin T et al (2009) Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging. J Clin Oncol 27:4082–4088CrossRefPubMedPubMedCentral
6.
go back to reference Wong SM, Freedman RA, Sagara Y et al (2016) Growing use of contralateral prophylactic mastectomy despite no improvement in long-term survival for invasive breast cancer. Ann Surg 265:581–589CrossRef Wong SM, Freedman RA, Sagara Y et al (2016) Growing use of contralateral prophylactic mastectomy despite no improvement in long-term survival for invasive breast cancer. Ann Surg 265:581–589CrossRef
7.
go back to reference Nichols HB, Berrington de Gonzalez A, Lacey JV et al (2011) Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol 29:1564–1569CrossRefPubMedPubMedCentral Nichols HB, Berrington de Gonzalez A, Lacey JV et al (2011) Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol 29:1564–1569CrossRefPubMedPubMedCentral
8.
go back to reference Uyeno L, Behrendt, Vito C (2012) Contralateral breast cancer: Impact on survival after unilateral breast cancer is stage-dependent. ASCO Breast Cancer Symposium Abstract vol 69 Uyeno L, Behrendt, Vito C (2012) Contralateral breast cancer: Impact on survival after unilateral breast cancer is stage-dependent. ASCO Breast Cancer Symposium Abstract vol 69
9.
go back to reference Bertelsen L, Bernstein L, Olsen JH et al (2008) Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the women’s environment, cancer and radiation epidemiology study. J Natl Cancer Inst 100:32–40CrossRefPubMed Bertelsen L, Bernstein L, Olsen JH et al (2008) Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the women’s environment, cancer and radiation epidemiology study. J Natl Cancer Inst 100:32–40CrossRefPubMed
10.
go back to reference Kurian AW, McClure LA, John EM et al (2009) Second primary breast cancer occurrence according to hormone receptor status. J Natl Cancer Inst 101:1058–1065CrossRefPubMedPubMedCentral Kurian AW, McClure LA, John EM et al (2009) Second primary breast cancer occurrence according to hormone receptor status. J Natl Cancer Inst 101:1058–1065CrossRefPubMedPubMedCentral
11.
go back to reference Brewster AM, Parker PA (2011) Current knowledge on contralateral prophylactic mastectomy among women with sporadic breast cancer. Oncologist 16:935–941CrossRefPubMedPubMedCentral Brewster AM, Parker PA (2011) Current knowledge on contralateral prophylactic mastectomy among women with sporadic breast cancer. Oncologist 16:935–941CrossRefPubMedPubMedCentral
12.
go back to reference Bouchardy C, Benhamou S, Fioretta G et al (2011) Risk of second breast cancer according to estrogen receptor status and family history. Breast Cancer Res Treat 127:233–241CrossRefPubMed Bouchardy C, Benhamou S, Fioretta G et al (2011) Risk of second breast cancer according to estrogen receptor status and family history. Breast Cancer Res Treat 127:233–241CrossRefPubMed
13.
go back to reference Khan SA (2011) Contralateral prophylactic mastectomy: what do we know and what do our patients know? J Clin Oncol 29:2132–2135CrossRefPubMed Khan SA (2011) Contralateral prophylactic mastectomy: what do we know and what do our patients know? J Clin Oncol 29:2132–2135CrossRefPubMed
14.
go back to reference Murphy JA, Milner TD, O’Donoghue JM (2013) Contralateral risk-reducing mastectomy in sporadic breast cancer. Lancet Oncol 14:e262–e269CrossRefPubMed Murphy JA, Milner TD, O’Donoghue JM (2013) Contralateral risk-reducing mastectomy in sporadic breast cancer. Lancet Oncol 14:e262–e269CrossRefPubMed
15.
go back to reference Abbott A, Rueth N, Pappas-Varco S et al (2011) Perceptions of contralateral breast cancer: an overestimation of risk. Ann Surg Oncol 18:3129–3136CrossRefPubMed Abbott A, Rueth N, Pappas-Varco S et al (2011) Perceptions of contralateral breast cancer: an overestimation of risk. Ann Surg Oncol 18:3129–3136CrossRefPubMed
17.
go back to reference Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9:45–53CrossRef Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9:45–53CrossRef
18.
go back to reference Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRef Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRef
19.
go back to reference Cuzick J, Sestak I, Baum M et al (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11:1135–1141CrossRefPubMed Cuzick J, Sestak I, Baum M et al (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11:1135–1141CrossRefPubMed
20.
go back to reference Chen Y, Thompson W, Semenciw R, Mao Y (1999) Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev 8:855–861PubMed Chen Y, Thompson W, Semenciw R, Mao Y (1999) Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev 8:855–861PubMed
21.
go back to reference Schaapveld M, Visser O, Louwman WJ et al (2008) The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat 110:189–197CrossRefPubMed Schaapveld M, Visser O, Louwman WJ et al (2008) The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat 110:189–197CrossRefPubMed
22.
go back to reference Graeser MK, Engel C, Rhiem K et al (2009) Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 27:5887–5892CrossRefPubMed Graeser MK, Engel C, Rhiem K et al (2009) Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 27:5887–5892CrossRefPubMed
25.
go back to reference Habel LA, Capra AM, Achacoso NS et al (2010) Mammographic density and risk of second breast cancer after ductal carcinoma in situ. Cancer Epidemiol Biomarkers Prev 19:2488–2495CrossRefPubMed Habel LA, Capra AM, Achacoso NS et al (2010) Mammographic density and risk of second breast cancer after ductal carcinoma in situ. Cancer Epidemiol Biomarkers Prev 19:2488–2495CrossRefPubMed
26.
go back to reference Hwang ES, Miglioretti DL, Ballard-Barbash R et al (2007) Association between breast density and subsequent breast cancer following treatment for ductal carcinoma in situ. Cancer Epidemiol Biomarkers Prev 16:2587–2593CrossRefPubMed Hwang ES, Miglioretti DL, Ballard-Barbash R et al (2007) Association between breast density and subsequent breast cancer following treatment for ductal carcinoma in situ. Cancer Epidemiol Biomarkers Prev 16:2587–2593CrossRefPubMed
27.
go back to reference Raghavendra A, Sinha AK, Le-Petross HT et al (2017) Mammographic breast density is associated with the development of contralateral breast cancer. Cancer 123:1935–1940CrossRefPubMedPubMedCentral Raghavendra A, Sinha AK, Le-Petross HT et al (2017) Mammographic breast density is associated with the development of contralateral breast cancer. Cancer 123:1935–1940CrossRefPubMedPubMedCentral
30.
go back to reference Breslow NE, Day NE (1980) Statistical Methods in Cancer Research. International Agency for Research on Cancer, Lyon Breslow NE, Day NE (1980) Statistical Methods in Cancer Research. International Agency for Research on Cancer, Lyon
32.
go back to reference Hosmer DW, Lemeshow S (2000) Applied Logistic Regression, 2nd ed. Wiley, hoboken Hosmer DW, Lemeshow S (2000) Applied Logistic Regression, 2nd ed. Wiley, hoboken
33.
go back to reference Development Core Team R (2016) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna Development Core Team R (2016) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna
35.
go back to reference Therneau TM, Grambsch PM (2000) Modeling survival data: extending the cox model. Springer, BerlinCrossRef Therneau TM, Grambsch PM (2000) Modeling survival data: extending the cox model. Springer, BerlinCrossRef
36.
go back to reference Murphy JA, Milner TD, O’Donoghue JM (2013) Contralateral risk-reducing mastectomy in sporadic breast cancer. Lancet Oncol 14:e262–e269CrossRefPubMed Murphy JA, Milner TD, O’Donoghue JM (2013) Contralateral risk-reducing mastectomy in sporadic breast cancer. Lancet Oncol 14:e262–e269CrossRefPubMed
Metadata
Title
Dose-dependent effect of mammographic breast density on the risk of contralateral breast cancer
Authors
Marzana Chowdhury
David Euhus
Maureen O’Donnell
Tracy Onega
Pankaj K. Choudhary
Swati Biswas
Publication date
01-07-2018
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2018
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-018-4736-8

Other articles of this Issue 1/2018

Breast Cancer Research and Treatment 1/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine